Centrally Acting Sympathomimetics. Lisdexamfetamine 10 mg/ml. Bottle, oral sol. 100 ml
ADHD: starting dosage in adults and ped. pts 6 years and older is 30 mg (equivalent to 3 ml) once/d in the morning. Dosage may be adj. in incr. of 10 mg (equivalent to 1 ml) or 20 mg (equivalent to 2 ml) at approx. weekly intervals up to max. dosage of 70 mg (equivalent to 7 ml) once/d.
Moderate to Severe BED in Adults: starting dosage in adults is 30 mg (equivalent to 3 ml) once /d to be titrated in incr. of 20 mg (equivalent to 2 ml) at approx. weekly intervals to achieve target dose of 50 to 70 mg (equivalent to 5 ml to 7 ml) once daily. The max. dosage is 70 mg/once daily (equivalent to 7 ml/once daily).
See prescribing info. for full details.
• Attention Deficit Hyperactivity Disorder (ADHD) in pts. ages 6 years and above.
• Mod. to Sev. Binge Eating Dis.(BED) for pts over 18 years.
C/I:Hypersens. Known hypersens. to amphetamine prod. Anaphylactic reactions, Stevens Johnson Syndrome, angioedema, and urticaria have been observed in post-marketing reports./Pts taking monoamine oxidase inhibit. (MAOIs), or within 14 days of stopping MAOIs (incl. MAOIs such as linezolid or intravenous methylene blue), because of an incr. risk of hypertensive crisis
NSAID. Flurbiprofen 8.75 mg. Spay solution,15 ml
One dose (3 actuations= 8.75 mg Flurbiprofen ) admin. to the back of the throat every 3-6 hs as required, up to a max. of 5 doses in 24 h
Short term symptomatic relief of acute sore throat in adults
C/I: Hypersens. /Pts with hypersens. reactions (e.g asthma, bronchospasm, rhinitis, angioedema or urticaria) to acetylsalicylic acid or other NSAIDs./Active, or hist. of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulcerat.) and intestinal ulcerat./Hist. of GI bleeding or perforation, sev. colitis, haemorrhagic or haematopoietic dis. related to previous NSAID ther./Last trim. of pregn. /Sev. HF, sev. renal fail. or sev. hepatic fail./Childr. and adolesc. below 18 years.
Janus Kinase Inhibitor (JAKs). Tofacitinib 5 mg. FC Tabs 60 X 5 mg
Rheumatoid arthritis:
5 mg twice/d, which should not be exceeded. No dose adjust. req. when used in comb. with methotrexate (MTX).
Psoriatic arthritis: 5 mg twice/d, which should not be exceeded.
No dose adjust. req. when used in comb. with MTX.
Ankylosing spondylitis: 5 mg twice/ d.
Ulcer. colitis –Induct. tmt.: 10 mg twice/d for 8 weeks.
For pts. who do not achieve adeq. therap. benefit by week 8, induct. dose can be extend. for an addit. 8 wks. (16 wks. total), followed by 5 mg twice/d for maint. Should be discont. in pts. who show no evid. of therap. benef. by wk. 16.
Ulcer. colitis –Mainten. tmt: 5 mg twice/d.
Juvenile idiopathic arthritis (JIA) dosing as per pt. weight:
betw 10 and 20 kg: 3. 2 mg X 2 dly
betw 20-40 kg: 4 mg X 2 dly
more than 40 kg: 5 mg X 2 dly. See full prescript. details
Rheumatoid arthritis: in combin. with methotrexate (MTX) for mod. to sev. active rheumatoid arthritis (RA) in adults who have respon. inadeq. to, or who are intol. to one or more dis.-modifying antirheumatic drugs (DMARDs). Can be given as monother. in case of intoler. to MTX or when MTX is inappropriate.Psoriatic arthritis: in combin. with MTX for active psoriatic arthritis (PsA) in adults who have had an inadeq. resp. or who have been intol. to a prior DMARD ther. Ulcerative colitis: for adults with moder. to sev. active ulcerative colitis (UC) who have had an inadeq. resp., lost resp, or were intol. to either convent. ther. or a bio. agent. Ankylosing spondylitis: for adults with active ankylosing spondylitis (AS) who have resp. inadeq. to convent. ther. Juvenile idiopathic arthritis (JIA): for active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in 2 years of age and older, who have resp. inadeq. to previous DMARDs. Can be given in combin. with MTX or as monother. in case of intoler. to MTX or where contin. tmt. with MTX is inapprop.
C/I: Hypersens. Active tuberc. (TB), serious infect. such as sepsis, or opportun. infect. • Severe hepatic impairm. • Pregn. and lactat.
Pazopanib 200 mg, 400 mg. Caps 200/400 mg X 30/60/90
800 mg once/d
Renal cell carcinoma (RCC): in adults for the first line tmt. of adv. RCC and for pts who have received prior cytokine ther. for adv. dis.
Soft tissue sarcoma (STS): for adult pts. with selective subtypes of adv. STS who have received prior chemother. for metast. dis. or who have progressed within 12 mo. after (neo) adjuvant ther.
C/I: Hypersens.
Kinase Inhibitor. momelotinib dihydrochloride 100 mg, 150 mg, 200 mg. FC Tab 30 X 100,150,200 mg
Daily dose: 200 mg. Not to be used with other JAK inhib. CBC and liver function to be tested before and during tmt.
Tmt. of intermediate or high-risk myelofibrosis (MF), including prim. MF or sec. MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.
C/I: Hypersens. Pregn. and lactat
Enzyme Cofactor. Sapropterin 100 mg. Sol. Tabs. 30,120 X 100 mg
PKU (Phenylketonuria)
starting dose in adult and paed. pts. is 10 mg/kg BW once daily. Dose to be adjusted, between 5 and 20 mg/kg/d, to maintain adequate blood phenylalanine levels.
BH4 deficiency
starting dose in adult and paed. pts. is 2 to5 mg/kg BW total daily dose. Doses may be adjusted up to 20 mg/kg/d.
Tmt.of hyperphenylalaninaemia (HPA) in adults and paed. pts. of all ages with phenylketonuria (PKU) who have been shown to be responsive to such tmt.
Tmt.of hyperphenylalaninaemia (HPA) in adults and paed.pts. of all ages with tetrahydrobiopterin (BH4) deficiency who have been shown to be responsive to such tmt.
CI: Hypersens.
השפעות BR11595 - אנטגוניסט לרצפטור P2X4 - במודל אסטמה כרונית בשרקנים
הקשר בין מחויבות מקצועית להתנהגות בטיחותית בקרב אחיות אונקולוגיות
נאופלזיה טרופובלסטית הריונית: השוואה בין שני משטרי טיפול
שכיחות זיהומי מגע מיני בנשים אפריקאיות המתחילות טיפול PrEP
השפעה של כימותרפיה נאו-אדג'ובנטית מלווה בניתוח על נשים עם סרטן שחלות
התועלת בבדיקות עצמיות ל-HIV ולעגבת ליישום טיפול בבן/ בת הזוג
לחץ דם גבוה כגורם סיכון לירידה קוגניטיבית
גורמים משפיעים על שיקול דעת קליני בקרב אחיות אונקולוגיות
השוואת הסיכון לאירועים קרדיווסקולריים חמורים בין אבירטרון אצטט לאנזלוטמיד בקרב מטופלים עם סרטן ערמונית גרורתי עמיד לסירוס
לעלון לצרכן לחצו כאן
הודעה על עדכון בעלון של התכשירים:
Cresemba 100 mg Capsules - לפרטים נוספים לחץ כאן
Cresemba 200 mg IV - לפרטים נוספים לחץ כאן
Ixifi - לפרטים נוספים לחץ כאן
Xanax X.R - לפרטים נוספים לחץ כאן
Diflucan 50mg/ml-לפרטים נוספים לחצו כאן
Trican 200 mg-לפרטים נוספים לחצו כאן
Triflucan I.V-לפרטים נוספים לחצו כאן
IXIFI-לפרטים נוספים לחצו כאן
Human Monoclonal Antibody. Avelumab 20 mg / ml. VIAL (conc. For sol. For infus.) 1 x 10 ml. MCC or UC: 800 mg or 10 mg/kg body weight, accord. to treat. Physician's discretion, admin. as a IV infus. over 60 min. every 2 wks. until dis. progress. or unacceptab. toxicity.
RCC: 800 mg or 10 mg/kg body weight, accord. to treat. Physician's discretion, admin. as a IV infus. over 60 min. every 2 wks. in comb. with axitinib 5 mg oral. taken twice daily until dis. progress. or unacceptab. toxicity. see lit.
Tmt. of adlt.pts. with metastat. Merkel cell carcinoma (MCC).
Maint. tmt. of pts. with local. adv. or metastat. urothelial carcinoma (UC) that has not progress. with first-line platinum-containing chemother.
Tmt. of pts. with local. adv. or metastat. urothelial carcinoma (UC) who:
- Have dis. progress. during or follow. platinum-containing chemother.
- Have dis. progress. within 12 months of neoadjuvant or adjuvant tmt.
with platinum-containing chemother.
First-line tmt. of pts. with adv. renal cell carcinoma (RCC) in comb. with axitinib.
C/I: Hypersens.
Centrally Acting Sympathomimetics. Lisdexamfetamine 10 mg/ml. Bottle, oral sol. 100 ml
ADHD: starting dosage in adults and ped. pts 6 years and older is 30 mg (equivalent to 3 ml) once/d in the morning. Dosage may be adj. in incr. of 10 mg (equivalent to 1 ml) or 20 mg (equivalent to 2 ml) at approx. weekly intervals up to max. dosage of 70 mg (equivalent to 7 ml) once/d.
Moderate to Severe BED in Adults: starting dosage in adults is 30 mg (equivalent to 3 ml) once /d to be titrated in incr. of 20 mg (equivalent to 2 ml) at approx. weekly intervals to achieve target dose of 50 to 70 mg (equivalent to 5 ml to 7 ml) once daily. The max. dosage is 70 mg/once daily (equivalent to 7 ml/once daily).
See prescribing info. for full details.
• Attention Deficit Hyperactivity Disorder (ADHD) in pts. ages 6 years and above.
• Mod. to Sev. Binge Eating Dis.(BED) for pts over 18 years.
C/I:Hypersens. Known hypersens. to amphetamine prod. Anaphylactic reactions, Stevens Johnson Syndrome, angioedema, and urticaria have been observed in post-marketing reports./Pts taking monoamine oxidase inhibit. (MAOIs), or within 14 days of stopping MAOIs (incl. MAOIs such as linezolid or intravenous methylene blue), because of an incr. risk of hypertensive crisis
Corticosteroid. Fluticasone Propionate 0.05%. METERED NASAL SPRAY: 120 doses. 2
sprays into ea. nostril 1 x dly. Child:
4-12 yrs: 1 spray into ea. nostril 1 x dly.
Under 4 yrs: Not recommended.
Proph. and tmt. seasonal allerg. rhinit.
incl. hayfever, perennial rhinit.
C/I: Hypersens. to compon.
5-α Reductase Inhibitor, α1 Blocker. Dutasteride 0.5 mg, Tamsulosin HCl 0.4 mg. 5-a Reductase Inhibitor/Alpha 1 Blocker. Dutasteride 0.5 mg, tamsulosin 0.4 mg.
CAPS: 30. 1 cap. dly. See lit.
Tmt. mod. to severe symp. BPH. Reduc. risk of acute urin. reten. (AUR) and surgery in pts. with mod. to severe sympt. of BPH.
C/I: Hyperses., women, child., adolesn., pts. with a hist. of orthost. hypotension, pts. with severe hepat. impair.
CCB, Local Anesthetic. Lidocaine HCl 1.5%, Nifedipine 0.3%. RECTAL CR.: 30g. Should be applied twice dly. for at least 3 wks. See lit.
Tmt. of anal fissures and proctolog. general. associate. with anal sphincter hypertonia.
C/I: Hypersens. to the active ingred., partic. to Lidocaine (& other local anesthet. with a similar amidic type structure). Presumed or ascertained preg. & lact.
Analgesic, Antipyretic, Opioid. Caffeine 50 mg, Codeine Phosphate 15 mg, Paracetamol 500 mg. CAPLETS: 12, 24. 1 capl. × 3-4 times/day. For severe pains - 2 capl. 3-4 times/day. Do not exceed a dosage of 8 capl. in 24 hrs. See lit.
For the relief of pain and coughs and for the reduction of fever accompanied by pain.
C/I: Hypersens. 1st & 3rd trim. of preg. Lact. Child. under 12 yrs. old. Adolesc. over 12 yrs. old and under 18 yrs. old after surg. remov. of their tonsils or adenoids. Concom. use with medic. contain. paracetamol /codeine. Pts. with respirat. depress. Pts. who are known as ultra-rapid metabolizer.
NSAID. Flurbiprofen 8.75 mg. Spay solution,15 ml
One dose (3 actuations= 8.75 mg Flurbiprofen ) admin. to the back of the throat every 3-6 hs as required, up to a max. of 5 doses in 24 h
Short term symptomatic relief of acute sore throat in adults
C/I: Hypersens. /Pts with hypersens. reactions (e.g asthma, bronchospasm, rhinitis, angioedema or urticaria) to acetylsalicylic acid or other NSAIDs./Active, or hist. of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulcerat.) and intestinal ulcerat./Hist. of GI bleeding or perforation, sev. colitis, haemorrhagic or haematopoietic dis. related to previous NSAID ther./Last trim. of pregn. /Sev. HF, sev. renal fail. or sev. hepatic fail./Childr. and adolesc. below 18 years.
Nicotine Receptor Partial Agonist. Varenicline (as tartrate) 0.5 mg, 1 mg. Health basket inclusion: Champix will be given to the treatment of smoking cessation parallel to supportive means.
TABS: 55 x 0.5 mg, 56 x 1 mg; starter pack: 11 x 0.5 mg + 14, 28 x 1 mg.
Days 1 – 3: 0.5 mg ×1/d.
Days 4– 7: 0.5 mg ×2/d.
Day 8 – end of tmt.: 1 mg ×2/d.
Pts. should be treated with Varenicline for 12 wks. For pts. who have successf. stopped smok. at the end of 12 wks., an addit. course of 12 wks. tmt. with Varenicline is recomm. to further incr. the likelihood of long-term abstinence.
Pts. with ren. impair. No dosage adjust. is necessary for pts. with mild- moder. renal impair. For pts. with sev. renal impair. (estimated CrCl <30 mL/min), the recomm. start. dose of Varenicline is 0.5 mg ×1/d. The dose may then be titrated as needed to a max. dose of 0.5 mg×2/d. For pts. with end-stage renal dis. underg. hemodialysis, a max. dose of 0.5 mg mg×/d may be admin. if toler.
Aid to smoking cessat. for adults over 18
yrs.
C/I: Hypersens., known skin react. to varenicline
